Carl Borrebaeck – professor and serial entrepreneur with a taste for speed

Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borreb...

From lab to patient – the art of developing new antibody therapies

For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along ...

Assignment: Facilitate the retention of foreign researchers

A newly appointed public inquiry is to develop measures to make attracting and retaining foreign doctoral students and researchers in Sweden easier.

Standardisation in automation

B. Braun Melsungen had a great idea and implemented it throughout the plant. Production for infusion solutions was to be largely standardised. B. Braun hoped th...

Nanexa finalist i Fierce Innovation Awards

Uppsalabolaget Nanexa har utsetts till finalist i den internationella tävlingen Fierce Innovation Awards Life Sciences. Bolaget uppmärksammas i kategorin Drug D...

Biogen fick nobben på utköpserbjudande

Sage Therapeutics styrelse säger nej till utköpserbjudandet från den betydligt större partnern Biogen.

Uppgift: Sanofi planerar avknoppning av sina receptfria läkemedel

Den franska läkemedelsjätten Sanofi uppges ha bett ett antal banker att pitcha för att delta i att hantera företagets planerade avknoppning av sin OTC-verksamhe...

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely e...

Ingrid Lönnstedt: Demystification of the power of a scientific study

”You surely do realize that even the smallest changes in study assumptions may influence the estimated sample size needed. And how is it even possible to guess ...

Babypuderskandalen når Europa – första stämningen mot J&J i Storbritannien

De enorma skadeståndsprocesserna mot Johnson & Johnson, vars talkpuder påstås ha orsakat cancer, har nu även nått Storbritannien.

The dock that “thinks” for itself

The world of bulk material handling seems straightforward at first glance: moving, filling, delivering. However, the art of dealing with a variety of different ...

Galenica AB

"Are we doing business the wrong way around in the Life Science Sector?"

For the past 50 years we have created solutions for problems that we thought would solve the problems. Pharmaceuticals have created big block buster drugs which...

Settlement of cancer allegations against blockbuster drug

French pharmaceutical company Sanofi has reached a principal agreement in the US on around 4,000 of the cases in which its now withdrawn blockbuster heartburn d...

Ny styrelseordförande för Anacardio

Michael Grissinger har utsetts till ny ordförande för Anacardios styrelse.

Accelerate your Research with AI-Powered Image Analysis

Comprehensive eBook from ZEISS.

SGS Fimko beviljas status som anmält organ enligt IVD-förordningen

Helsingfors, 21.10.2025 / SGS Fimko Oy har nått en betydande milstolpe i och med att den Europeiska kommissionen officiellt har utsett företaget till ett anmält...

Texas stämmer Tylenol-tillverkare – anklagas för att ha dolt påstådd autismkoppling

Texas justitieminister stämmer Johnson & Johnson och dess avknoppning Kenvue för att ha dolt misstänkta risker med smärtstillande läkemedlet Tylenol, kopplade t...

The new ZEISS Celldiscoverer 7 has been launched

Adaptable automation for advanced workflows.

Anna Törner: The clinical trial – Periscope to reality

What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.

Rising interest in CRISPR treatments

Treatments using CRISPR technology are emerging as one of the hottest medical trends in the United States – and the FDA is doing its best to promote the development.

Scientific Solutions

CTC Clinical Trial Consultants AB

Galderma